Clinical trial
A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation
NCT01246206 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- October 31, 2013
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hematological malignancies